HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
REGN
Regeneron Pharmaceuticals Inc
Healthcare Biotechnology · New York, USA · Reports in usd
Market Cap: $74.75B
Market Cap
$74.75B
Enterprise Val
$68.70B
P/E Ratio
16.90
P/B Ratio
2.38
Trailing PEG (1Y)
-2.17
As Of
Apr 29, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$31.42B
Gross Margin81.43%
Profit Margin81.43%
Return on Equity14.32%
Return on Assets11.07%
Current Ratio3.57
Debt/Equity0.09
LT Debt/Equity0.06
Revenue Per Share34.10

Income Statement

Mar 31, 2026
Revenue$3.61B
Cost of Revenue$669.4M
Gross Profit$2.94B
R&D$1.54B
SG&A$647.7M
Operating Expenses$2.29B
Operating Income$642.9M
Interest Expense$12.9M
Tax Expense$104.0M
Net Income$727.2M
EPS (Basic)$6.99
EPS (Diluted)$6.75
EBIT$844.1M
EBITDA$967.3M
Consolidated Income$727.2M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$2.96B
Accounts Receivable$5.73B
Inventory$3.10B
Current Assets$18.21B
LT Investments$9.79B
Property, Plant & Equipment$5.27B
Intangibles$1.29B
Non-Current Assets$22.66B
Total Assets$40.87B
Accounts Payable$1.03B
Current Debt$720.0M
Current Liabilities$5.11B
LT Debt$1.99B
Non-Current Liabilities$4.34B
Total Liabilities$9.45B
Total Debt$2.71B
Retained Earnings$36.42B
Shareholder Equity$31.42B
Shares Outstanding105,719,806

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow$1.08B
Investing Cash Flow-$428.9M
Financing Cash Flow-$802.2M
CapEx-$230.6M
Free Cash Flow$848.3M
Depreciation & Amort.$123.2M
Stock-Based Comp$257.4M
Acquisitions / Disposals$0.00
Investment Activity-$149.4M
Debt Issued/Repaid$0.00
Equity Issued/Repaid-$704.4M
Dividends Paid-$97.8M
Net Change in Cash-$153.1M
Data cached · Meta live · Daily live · Statements live · TTL 24h